The joint pain reliever Flexagene claims to be a ‘breakthrough’ innovation in joint treatment containing ingredients that won an ‘Innovation in Research’ award. The general tone of the official Flexagene website is highly exaggerated and a large part of the site focuses on the ordering process.
What information there is regarding the Flexagene product itself is detailed and easy for consumers to understand. A biography and personal letter from the developer of the Flexagene formula, Dr. Bruce Dooley, is provided but, apart from a few very brief statements, no consumer testimonials or FAQ section is shown.
The ‘3 free bottle’ offer is somewhat misleading, as this is only applicable to orders of 3 bottles or more, although multiple orders do entitle the consumer to free gifts such as an alternative health newsletter and prescription discount card. Flexagene is only available to purchase from the main website, not in independent retail stores.
Flexagene – Facts
Unlike most traditional joint pain relievers, Flexagene does not contain Glucosamine or Chondroitin, nor does it have a Cox-2 inhibitor effect. Instead it combines two plant extracts, Vincaria, from the Uncaria Guianensis plant, and RN1-249, derived from Lepidium Meyenii, which help reduce inflammation and rebuild joints respectively. According to the website, Vincaria is able to actually ‘switch off’ inflammation – the main cause of joint pain – at its source, whereas RN1-249 boosts the body’s IGF-1 levels, a ‘youth’ hormone responsible for not only rejuvenating bones, cartilage and muscle, but for having an all-over anti-aging effect.
The two active ingredients are combined in a proprietary formula so unfortunately the exact amounts contained in each dose are not known and both ingredients are still undergoing clinical testing.
- Flexagene is a shellfish-free alternative to Glucosamine
- No side effects have been reported
- Free gifts and discounts are offered for multiple orders
- Detailed explanations of the ingredients are provided
- The product works in two ways to reduce pain-causing inflammation and rebuild joints
- The company provides a 100% money-back guarantee
- The customer has the option to be enrolled in the auto-shipping program
- Flexagene is expensive, costing $59.95 per one month supply
- No dosage instructions are provided
- The company website is over-exaggerated and misleading
- No completed clinical studies are provided
- No customer testimonials are available
- Flexagene is not available in retail stores
- Flexagene does not contain a joint lubricant
- The exact ingredient amounts are unknown
- No positive independent consumer reviews are available
There is no way of knowing whether the ingredients Vincaria and RN1-249 are really a ‘breakthrough’ in joint health or not, given that clinical studies are ongoing. It is true that Flexagene does address the major cause of most joint pain – inflammation – and, if Vincaria was found to be as innovative as is claimed, it would make it a good alternative for those who cannot tolerate Glucosamine.
Unfortunately there is simply too little concrete evidence available right now to justify the expensive cost of this product.
Top Joint Pain Relief Products
**This is a subjective assessment based on the strength of the available information and our estimation of efficacy.
*Results may vary. If you are pregnant, nursing, have a serious medical condition, or have a history of heart conditions we suggest consulting with a physician before using any supplement. The information contained in this website is provided for general informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be relied upon as medical advice. Always consult your doctor before using any supplements.
Disclosure of Material Connection: Some of the links in the post above are "associate sales links." This means if you click on the link and purchase an item, we will receive a commission. Regardless, we only recommend products or services which we use personally and/or believe will add value to our readers. We are disclosing this in accordance with the Federal Trade Commission's 16 CFR, Part 255: "Guides Concerning the Use of Endorsements and Testimonials."